Barclays PLC Tyra Biosciences, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 43,070 shares of TYRA stock, worth $518,132. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,070

Previous 37,625 14.47%

Holding current value

$518,132

Previous $884,000 32.24%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$13.9 - $28.61 $75,685 - $155,781	5,445 Added 14.47%	43,070 $599,000
Q3 2024 Nov 15, 2024	BUY	$16.7 - $24.36 $419,270 - $611,582	25,106 Added 200.54%	37,625 $884,000
Q2 2024 Aug 14, 2024	BUY	$14.45 - $20.22 $38,567 - $53,967	2,669 Added 27.1%	12,519 $201,000
Q1 2024 May 15, 2024	SELL	$11.61 - $20.0 $108,866 - $187,540	-9,377 Reduced 48.77%	9,850 $161,000
Q4 2023 Feb 15, 2024	BUY	$11.01 - $14.95 $184,098 - $249,978	16,721 Added 667.24%	19,227 $266,000
Q3 2023 Nov 07, 2023	SELL	$13.15 - $16.08 $3,708 - $4,534	-282 Reduced 10.11%	2,506 $34,000
Q2 2023 Aug 03, 2023	SELL	$11.99 - $17.51 $47,924 - $69,987	-3,997 Reduced 58.91%	2,788 $48,000
Q1 2023 May 04, 2023	BUY	$6.85 - $16.22 $21,947 - $51,968	3,204 Added 89.47%	6,785 $109,000
Q4 2022 Feb 13, 2023	BUY	$5.68 - $8.81 $17,182 - $26,650	3,025 Added 544.06%	3,581 $27,000
Q3 2022 Nov 03, 2022	SELL	$6.61 - $12.42 $674 - $1,266	-102 Reduced 15.5%	556 $5,000
Q2 2022 Aug 12, 2022	SELL	$5.26 - $11.19 $6,611 - $14,065	-1,257 Reduced 65.64%	658 $5,000
Q1 2022 May 16, 2022	BUY	$10.03 - $14.09 $19,207 - $26,982	1,915 New	1,915 $20,000

Others Institutions Holding TYRA

# of Institutions

112

Shares Held

43.1M

Call Options Held

3.8K

Put Options Held

View Full List

About Tyra Biosciences, Inc.

Ticker TYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,973,600
Market Cap $505M
Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...

More about TYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account